Loading company…
PhecdaMed develops biopharmaceuticals focused on mitochondrial research.
PhecdaMed researches small-molecule mitochondrial autophagy inducers and tumor immune enhancers. Its compound TJ0113 targets kidney, autoimmune, and aging-related diseases. The company generates revenue through drug candidate licensing, grants, and pharmaceutical partnerships. Founded in 2021, it is based in Hangzhou, China, and raised Series A+ funding in September 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in